Nauzex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nauzex

Nauzex is a specialized synthetic medication primarily used to relieve symptoms associated with reduced movement in the upper digestive tract. Its active ingredient is Domperidone, which acts on the body's natural chemical messengers to regulate gastrointestinal function and counteract the sensation of sickness.


Property Description
Active ingredient Domperidone
Form Tablets, Oral Suspension, Oral Drops
Pharmacological class Dopamine Receptor Antagonist
Common use Relief of nausea and vomiting
Origin Synthetic organic molecule

What Type of Medicine is Nauzex and Its Main Purpose?

Nauzex belongs to the pharmacological group of Dopamine Antagonists and is specifically known as a prokinetic agent. The active compound, Domperidone, is a single-component, synthetic organic molecule. Its classification as a peripherally selective agent is clinically recognized for minimizing penetration across the blood-brain barrier. This specialization allows the medication to address issues such as feelings of prolonged stomach fullness or discomfort, in addition to its anti-sickness effects. The molecule is officially tracked under ATC code A03FA03.

Composition and Physical Forms of Nauzex

The formulation of Nauzex utilizes Domperidone as the sole active pharmaceutical ingredient, confirming it as a single-component product. The medicine is manufactured in various high-level dosage forms, including conventional oral tablets and liquid forms such as oral suspension or drops. These different preparations, primarily intended for oral administration, ensure flexibility for specific patient groups, such as children or the elderly, who may find swallowing solid tablets challenging.

General Principle: How Domperidone Affects Digestion

The therapeutic effect of Nauzex is achieved through a targeted, dual mechanism. Domperidone works by blocking specific dopamine receptors at the chemoreceptor trigger zone, which is critical for initiating the vomiting reflex. Furthermore, it stimulates the natural muscle contractions (peristalsis) in the stomach wall, facilitating a quicker process of gastric emptying. This combined action helps normalize the digestive flow and provides effective relief from symptoms like nausea and gastric sluggishness.

What side effects are possible with Nauzex?

Possible side effects and safety information

The safety profile of Nauzex (Domperidone) is documented in regulatory sources by classifying potential adverse reactions according to the organ system affected and their reported frequency.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (occurring in more than 1 in 100 people) primarily include dry mouth. Reactions classified as Uncommon (occurring in less than 1 in 100 people) involve systems such as the nervous system (e.g., somnolence, headache) and psychiatric disorders (e.g., anxiety, nervousness). Breast-related effects, such as breast pain or galactorrhoea, are also listed as Uncommon under the Reproductive System and Breast Disorders category.

Serious and Cardiovascular Safety

Official labeling specifically highlights the potential for Very Rare serious adverse reactions involving the heart. These risks include the potential for QTc prolongation, ventricular arrhythmias, and sudden cardiac death. These cardiac events are associated with the use of higher daily doses or long-term exposure to the medicine.

Population and Condition Constraints

The official safety information outlines specific constraints related to patient health status. The medicine is contraindicated (should not be used) in individuals with pre-existing conditions such as moderate or severe hepatic impairment, underlying cardiac diseases (e.g., congestive heart failure), or existing prolongation of cardiac conduction intervals. Additionally, an increased risk of serious cardiac events is noted for patients older than 60 years.

Overdose and Emergency Response

Overdose and when to seek help

Immediate medical attention is required upon any confirmed or suspected overdose of Nauzex (Domperidone). This urgency is driven by the potential for serious adverse effects on the heart and nervous system, as documented in regulatory labeling.

Feature Official Regulatory Statement
Documented Manifestations Overdose signs may include somnolence (drowsiness), disorientation, agitation, convulsions, and extrapyramidal reactions (involuntary movements).
Severe Outcomes The official label documents the risk of QT interval prolongation, ventricular arrhythmias, and potential for sudden cardiac death.
Emergency Action Individuals should seek immediate medical attention and may contact a poison control center, as this is a medical emergency.
Antidote Status No specific antidote is known for Domperidone overdose.

Management and Monitoring

Management procedures described in official documents are centered on providing symptomatic and supportive treatment. Measures such as gastric lavage or the administration of activated charcoal may be considered if performed shortly after ingestion. Due to the severe cardiovascular risks, close observation and continuous ECG monitoring are necessitated by regulatory advisories.

Population-specific overdose notes indicate that the documented extrapyramidal signs are more likely to happen in children. The higher risk of serious cardiac events is also emphasized in individuals over 60 years of age or those taking higher-than-recommended doses, requiring heightened caution in these overdose scenarios.

Therapeutic Uses of Nauzex

Nauzex may be part of symptomatic management, applied for conditions characterized by physical discomfort and temporary instability.

Managing Acute Symptom Patterns

The therapeutic domain of Nauzex is considered relevant for easing symptoms associated with acute or episodic changes, and it is applied across domains where additional symptomatic support is needed. This class of medicine is generally applied in addressing symptoms related to physical discomfort. Nauzex may be part of symptomatic management for conditions presenting with acute episodes, where symptoms may include discomfort related to systemic imbalance, heightened physiological activity, or functional stress.


Supporting Stability and Comfort

Nauzex is considered relevant in conditions characterized by periods of heightened symptoms or episodic manifestations. It is commonly used when symptoms intensify and supportive relief is needed, and is applied in clinical settings that involve acute or unstable symptom patterns. By easing distress and contributing to improved comfort, the medicine helps maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. European Medicines Agency guidance on Domperidone-containing medicines

Eligibility and Restrictions for Use

Who Can and Cannot Use Nauzex? (Domperidone)

The population eligibility for Nauzex is strictly governed by cardiac and hepatic safety restrictions, as defined by major regulatory agencies. Use is generally restricted to patients without specific underlying health conditions.


Populations for Whom Use is Contraindicated

Official regulatory documents state Nauzex must not be used by patients with:

  • Known underlying cardiac conditions, including QTc prolongation, congestive heart failure, significant bradycardia, or electrolyte disturbances.
  • Moderate or severe hepatic impairment (liver dysfunction).
  • Conditions where stimulating gastric motility could be harmful (e.g., gastro-intestinal hemorrhage or perforation).
  • A prolactin-releasing pituitary tumour.

Age and Restricted Use

Population Eligibility Status
Adults and Adolescents Approved for use in individuals 12 years of age and older and weighing 35 kg or more.
Children Not recommended for children under 12 years (efficacy not established).
Older Adults Use with caution due to a higher observed risk of serious ventricular arrhythmias.
Severe Renal Impairment Requires a regulatory reduction in dosing frequency.
Pregnancy/Lactation Not recommended; a decision must weigh the risk to the infant against the benefit to the mother.

Use for all eligible populations should not usually exceed one week.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Nauzex (Domperidone) is defined by constraints against substances that modify its systemic exposure or increase cardiac risk. Co-administration is strictly contraindicated with two major drug categories.

The first category includes Potent CYP3A4 Inhibitors, which block the drug's primary metabolic pathway (CYP3A4), leading to increased plasma concentrations. This group includes systemic azole antifungals (e.g., ketoconazole) and certain macrolide antibiotics (e.g., erythromycin). The second consists of QTc-Prolonging Medicinal Products, co-administration of which creates an additive pharmacodynamic effect, substantially increasing the risk of serious ventricular arrhythmias.

Specific restrictions and constraints apply:

  • Absorption: Certain Antacids or Antisecretory Agents are documented to reduce the oral bioavailability of Domperidone. Simultaneous administration is not advised, and a timing separation between the medicines is required.
  • Substance Restriction: Co-administration with Grapefruit Juice is contraindicated.
  • Population Constraint: The drug is contraindicated in patients with Moderate or Severe Hepatic Impairment due to reduced clearance and in those with significant Electrolyte Disturbances, as these conditions amplify the risk associated with the drug.

Mechanism of Action

Nauzex is a formulation of ondansetron, a carbazole derivative. Its primary biological targets are the 5- HT3 receptors, which are ligand-gated ion channels located in both peripheral and central nervous systems.

The compound functions as a highly selective antagonist at these 5- HT3 receptors. In the peripheral nervous system, this interaction occurs on vagal nerve terminals and in the gastrointestinal tract, where the blockade prevents the binding of serotonin and subsequent ion channel activation. Centrally, the antagonism is executed in the chemoreceptor trigger zone, an area outside the blood-brain barrier.

The molecular consequence of this antagonism is the inhibition of rapid neuronal depolarization and the suppression of the associated downstream signaling cascades that transmit emetic stimuli. This action results in a system-level modulation that limits afferent vagal and humoral signaling to the central vomiting centers, decreasing the excitability of these medullary nuclei.

Dosage and Administration Information

How to Use Nauzex

Nauzex (Domperidone) is administered according to a protocol focusing on defined dose limits and duration of use. The medication is primarily intended for short-term administration, with the treatment course typically advised not to exceed seven days.


Administration and Dosing

Nauzex is available for Oral administration (tablets, suspension) and, in some regions, Rectal administration (suppositories). The dosing schedule is defined by age and body weight:

Population Unit Dose Frequency Maximum Daily Dose
Adults & Adolescents (≥ 12 yrs and ≥ 35 kg) 10 mg (Oral) Up to three times daily 30 mg (Oral)
Pediatric (Children <12 yrs or <35 kg) 0.25 , mg/kg (Oral Suspension) Up to three times daily 0.75 , mg/kg

Oral doses must be separated by an approximate 8-hour interval. For patients with severe renal impairment, the dosing frequency must be reduced to once or twice daily for repeated administration.


Timing and Preparation

For optimal absorption, the medicine is generally recommended to be taken 15 to 30 minutes before meals. If a dose is missed, it must be omitted, and the regular schedule should be resumed with the next scheduled dose; doses must not be doubled to compensate for a missed administration. Furthermore, tablets and suppositories are unsuitable for children weighing less than 35 kg, who must use the liquid oral formulation for accurate, weight-based dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nauzex


Evidence for Relief of Nausea and Vomiting Symptoms

Research exploring Nauzex for symptoms of nausea and vomiting primarily involves short-term, randomized controlled trials (RCTs) that were conducted to examine the medicine in adults and adolescents (age 12 and older). These studies were used in research exploring how symptoms change over time. Specific research also explored this use in children (ages 6 months to 12 years); the research data was subject to detailed scientific review.

In these research scenarios, studies monitored the frequency and duration of vomiting episodes, as well as patient-reported outcomes describing perceived discomfort from nausea. Research monitored the number of vomiting episodes, providing data on symptom frequency in the observed populations. Research also explored outcomes related to the time it took for symptoms to evolve or reach a defined endpoint.


Evidence for Upper Digestive Tract Motility Support

Nauzex was also evaluated in studies examining temporary physiological imbalance and was applied in research contexts involving fluctuating or unstable symptoms. This research examined the compound when studied for its prokinetic characteristics. The study types available include RCTs, as well as data from longer-term, non-randomized observational settings that evaluated patients with conditions characterized by functional limitations, such as gastroparesis.

Studies monitored both patient-reported outcomes describing perceived discomfort, such as upper abdominal bloating, fullness, and early satiety, and objective outcomes. Studies reported measurements of gastric emptying rate in observed populations, reporting measurements of this physiological measure, while findings related to patient-reported symptoms were mixed across studies. Reports from specialized observational settings provided data observing changes in symptoms over extended time intervals in specific cohorts of patients whose symptoms were difficult to manage.


What is Still Uncertain About the Nauzex Evidence Base

Research contributes to the broader evidence landscape, but evidence highlights what is known—and what is still uncertain. One key uncertainty relates to the consistency of findings across different patient groups, particularly when comparing objective physiological outcomes (like the gastric emptying rate) with patient-reported outcomes describing perceived discomfort.

Regulators and scientific bodies acknowledge that long-term effects are not fully established through controlled research, meaning follow-up durations were limited for high-quality evidence, and certainty remains low regarding the full range of long-term outcomes. The research provides insight into short-term changes, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Nauzex (FAQ)


Q: Can Nauzex be taken with common over-the-counter pain relievers?

A: Official information does not specifically list common over-the-counter pain relievers, like acetaminophen or ibuprofen, as being strictly forbidden to take with Nauzex. However, regulatory documents advise against taking Nauzex with any medicine known to strongly interfere with its metabolism (CYP3A4 inhibitors) or those known to affect the heart’s electrical activity (QTc prolongation).


Q: Will Nauzex interact with common supplements like multivitamins or herbal teas?

A: Official product information advises that the medicine should not be taken with grapefruit juice or with certain herbal supplements. This is due to a lack of complete testing for potential interactions that could increase the risk of side effects. A professional can provide guidance regarding the use of supplements and the medicine.


Q: Can Nauzex be prescribed for children?

A: Nauzex is authorized for the relief of nausea and vomiting only in adults and adolescents 12 years of age or older and weighing at least 35 kilograms. According to regulatory agencies, it is generally not recommended for children younger than 12 years due to a lack of established evidence for its effectiveness in this age group.


Q: Is Nauzex safe to use during pregnancy or while breastfeeding?

A: Official guidance states that Nauzex is not recommended during pregnancy unless the potential benefit is judged to significantly outweigh the risk. Only small amounts of the medicine may pass into breast milk; therefore, its use during breastfeeding requires a professional to review the potential risk to the infant against the benefit to the mother.


Q: Can Nauzex be used if I have kidney issues?

A: Patients with severe renal impairment (significant kidney issues) must have their dosing frequency reduced, as specified in product prescribing information. Official recommendations generally state that dose adjustments are not typically required for patients with milder kidney problems.


Q: Does Nauzex affect my ability to drive or operate machinery?

A: Yes, official product information advises caution. Because some users have reported side effects such as somnolence (drowsiness) or dizziness, patients who experience somnolence or dizziness are officially advised to avoid driving or operating machinery until the effects are known.


Q: What is the list of ingredients in Nauzex?

A: The active ingredient in Nauzex is Domperidone. The product also contains inactive ingredients, called excipients, which are necessary to form the tablet or suspension. These inactive ingredients vary based on the specific formulation and manufacturer but typically include starches, cellulose, and other compounds.


Q: Is Nauzex the same type of medicine as anti-nausea drugs I've used before?

A: Nauzex is classified as a Dopamine Antagonist and is also known as a prokinetic agent. While it is an anti-sickness medicine, it belongs to a specific pharmacological class that may differ from other common anti-nausea drugs, such as certain antihistamines, which work differently in the body.


Q: Are there any specific foods or drinks I should avoid while taking Nauzex?

A: Official guidance strictly contraindicates co-administration with grapefruit juice, meaning it must be avoided. Other than this specific restriction, official information generally indicates that patients can eat and drink normally, although the medicine is typically recommended to be taken before meals.


Q: Is it true that alcohol should be avoided entirely while on Nauzex?

A: Official patient information often advises patients to avoid alcohol while taking Nauzex. This is because alcohol may potentially worsen some of the common side effects of the medicine, such as drowsiness or dizziness.


Q: Why do some users on forums mention feeling tired after taking Nauzex?

A: Official product information notes that feelings of tiredness or weakness, medically termed asthenia, are a reported adverse reaction. Additionally, somnolence (drowsiness) is also listed as an Uncommon side effect in regulatory documents, which may contribute to the feeling of feeling tired.


Q: Are there different strengths or formulations of Nauzex available?

A: Yes, Nauzex is commonly available in a standard 10 mg tablet strength for adults and adolescents. Other formulations, such as an oral suspension or oral drops, are also available and are necessary for accurate, weight-based dosing in the pediatric population.


Q: Is Nauzex known to interact with birth control pills?

A: Regulatory guidance states that Nauzex is generally not expected to affect how any type of hormonal contraception works. This includes combined oral contraceptives and progestogen-only pills.


Q: Are there any long-term side effects associated with Nauzex use?

A: The medicine is generally advised for short-term use only, typically not exceeding one week. This is because long-term exposure has been associated with a potentially increased risk of serious cardiovascular events. Official research notes that long-term effects are not fully established through controlled studies.


Q: Can I take Nauzex if I have a history of liver problems?

A: Nauzex is contraindicated (must not be used) in patients who have moderate or severe hepatic impairment (liver dysfunction). The use of the medicine in patients with a history of milder liver problems should be reviewed by a professional to determine appropriateness.


Q: Does Nauzex have a high risk of drug dependency?

A: The medicine is generally not described as habit-forming in regulatory documents. However, abrupt discontinuation of the medicine, particularly following unauthorized long-term use, has been associated with reports of withdrawal events like anxiety and nervousness.


Q: What makes Nauzex different from other medications used for similar purposes?

A: Nauzex is a Dopamine Antagonist that works in two primary ways: by blocking the vomiting reflex, and by stimulating movement (a prokinetic effect) in the gut. This specific combination of actions is a key feature that distinguishes it from many other types of anti-sickness medicines.


Q: What level of evidence supports the use of Nauzex?

A: The authorized use of Nauzex is supported by scientific data derived from research studies, including randomized controlled trials (RCTs) and specialized observational settings. This evidence has undergone detailed scientific review by regulatory bodies to establish its profile for efficacy and safety.


Q: Is a headache a common side effect reported for Nauzex?

A: Headache is reported as an Uncommon side effect in regulatory documents, meaning it affects fewer than 1 in 100 people who use the medicine. The most frequently reported adverse reaction, classified as Common, is dry mouth.


Q: Does Nauzex have any known severe allergic reaction risks?

A: Yes, official safety information lists Anaphylactic reaction (a severe allergic reaction, including anaphylactic shock) as a very rare potential adverse reaction. Signs of this reaction, such as sudden swelling or difficulty breathing, require immediate professional medical attention.


Q: Is Nauzex available over-the-counter in any country?

A: While Nauzex is a prescription-only medicine in many major markets, including the US, Canada, and the UK, official reports indicate that it is available as an over-the-counter (OTC) product in a number of other jurisdictions globally.


Q: Will Nauzex interact with common diabetes medications?

A: Official information does not contraindicate all diabetes medications with Nauzex. However, the medicine should not be used with any drugs that are strong inhibitors of the CYP3A4 metabolic pathway. Some diabetes medications have been documented to potentially have this interaction.


Q: What are the common misunderstandings about how Nauzex is supposed to be taken?

A: Common points of official clarification include the importance of taking the medicine before meals for optimal absorption. Official guidance emphasizes the importance of adherence to the maximum dose and duration (typically one week), and specifies that a missed dose should not be doubled.


Q: Are there any specific lifestyle changes recommended when starting Nauzex?

A: Official patient guidance primarily recommends avoiding alcohol due to the potential to worsen side effects like drowsiness. Official guidance recommends caution regarding driving or operating machinery if the user experiences somnolence (drowsiness).


Q: Does the FDA or other agencies have a specific safety alert for Nauzex?

A: Yes, major regulatory agencies, including the US FDA and Health Canada, have issued specific safety warnings regarding the potential for serious adverse cardiac events. These risks, such as QTc prolongation and sudden cardiac death, are particularly associated with higher doses or use in susceptible patient populations.

How should Nauzex be stored and disposed of?

How to Store and Dispose of Nauzex (Domperidone)

Nauzex must be stored according to regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C.
Protection Protect from light and moisture. Must be kept from freezing and excessive heat.
Packaging Store in the original container and keep it tightly closed.

The medicine must always be stored out of the reach and sight of children.

Disposal Instructions

Do not use Nauzex past the expiration date. Expired or unused medication must not be disposed of in household trash or flushed down the sink or toilet. Disposal must follow local pharmaceutical waste regulations, typically involving returning the product to a pharmacy or designated collection site for safe handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nauzex found in:

A-Z Index: